Posted On: 07/05/2016 2:51:50 PM
Post# of 23063
$AMPE: Ampio Hosting Conference Call Today, July 5, 4:30pm ET
1:30 PM ET 7/5/16 | PR Newswire
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) hosting a conference call today Tuesday, July 5th at 4:30pm ET. Participants are invited to dial in using the instructions as follows:
Investor call information: U.S./Canada toll-free number: 866-675-4790International toll number: 913-312-0685Participant Passcode: 4091988
https://photos.prnewswire.com/prnvar/20120516/MM09116LOGO
Questions can be emailed to April Ramirez, aramirez@ampiopharma.com.
About Ampio PharmaceuticalsAmpio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Forward Looking Statements Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the Ampion(TM) trial, as well as risks associated with clinical trials, expected results, obtaining requested meetings with the FDA, decisions by the FDA, requesting regulatory approval of Ampion(TM), and changes in business conditions and similar events. These forward-looking statements also include statements regarding the Special Protocol Assessment (SPA) as well as the classification of Ampion(TM) as a novel biologic with 12 years exclusivity. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Company ContactGregory A. GouldChief Financial OfficerPhone: (720) 437-6500ggould@ampiopharma.com
Logo - http://photos.prnewswire.com/prnh/20120516/MM09116LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ampio-hosting-conference-call-today-july-5-430pm-et-300294076.html
1:30 PM ET 7/5/16 | PR Newswire
Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) hosting a conference call today Tuesday, July 5th at 4:30pm ET. Participants are invited to dial in using the instructions as follows:
Investor call information: U.S./Canada toll-free number: 866-675-4790International toll number: 913-312-0685Participant Passcode: 4091988
https://photos.prnewswire.com/prnvar/20120516/MM09116LOGO
Questions can be emailed to April Ramirez, aramirez@ampiopharma.com.
About Ampio PharmaceuticalsAmpio Pharmaceuticals, Inc. is a development stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. We are developing compounds that decrease inflammation by (i) inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; (ii) activating specific phosphatase or depletion of the available phosphate needed for the inflammation process; and (iii) decreasing vascular permeability.
Forward Looking Statements Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to the Ampion(TM) trial, as well as risks associated with clinical trials, expected results, obtaining requested meetings with the FDA, decisions by the FDA, requesting regulatory approval of Ampion(TM), and changes in business conditions and similar events. These forward-looking statements also include statements regarding the Special Protocol Assessment (SPA) as well as the classification of Ampion(TM) as a novel biologic with 12 years exclusivity. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Company ContactGregory A. GouldChief Financial OfficerPhone: (720) 437-6500ggould@ampiopharma.com
Logo - http://photos.prnewswire.com/prnh/20120516/MM09116LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ampio-hosting-conference-call-today-july-5-430pm-et-300294076.html
(0)
(0)
